D2 dopamine-receptor-mediated inhibition of proliferation of rat lactotropes in culture is accompanied by changes in cell shape

Neuroendocrinology

Volumn 68, Issue 3, 1998, Pages 163-171

  Arita, Jun ^a   Hashi, Akihiko ^a   Hoshi, Kazuhiko ^a   Mazawa, Sachiko ^a   Suzuki, Shinichi ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Bromocriptine; Catecholamines; Lactotrope; Proliferation

Indexed keywords

ACTIN; BROMOCRIPTINE; BROXURIDINE; DOPAMINE; DOPAMINE 2 RECEPTOR; ETICLOPRIDE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; SALICYLAMIDE DERIVATIVE;

ACTIN FILAMENT; ADENOHYPOPHYSIS; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL SHAPE; CELLULAR DISTRIBUTION; FEMALE; GROWTH INHIBITION; HYPOPHYSIS CELL; IMMUNOFLUORESCENCE; NONHUMAN; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; RAT; ANIMAL; CELL DIVISION; CELL SIZE; CELL SURVIVAL; CULTURE MEDIUM; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PHYSIOLOGY; TIME;

ACTINS; ANIMALS; BROMOCRIPTINE; CELL DIVISION; CELL SIZE; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; MICROSCOPY, PHASE-CONTRAST; PITUITARY GLAND, ANTERIOR; PROLACTIN; RATS; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; TIME FACTORS;

EID: 0031595935     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054362     Document Type: Article

References (54)

1. Ben-Jonathan N: Dopamine: A prolactin inhibiting hormone. Endocr Rev 1985;6:564-589.
2. Jacobi JM, Lloyd HM: Modulation by dopamine antagonists of DNA synthesis in the pituitary gland of the male rat. Neuroendocrinology 1981;33:97-100.
3. Lu KH, Koch Y, Meites J: Direct inhibitory by ergocornine of pituitary prolactin release. Endocrinology 1971;89:229-233.
4. Lloyd HM, Meares JD, Jacobi J: Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature 1975;255: 497-498.
5. Kalbermann LE, Machiavelli GA, De Nicola AF, Weissenberg LS, Burdman JA: Synthesis of DNA in oestrogen-induced pituitary tumours in rats: Effect of bromocriptine. J Endocrinol 1980;87:221-224.
6. Pérez RL, Machiavelli GA, Romano MI, Burdman JA: Prolactin release, oestrogens and proliferation of prolactin-secreting cells in the anterior pituitary gland of adult male rats. J Endocrinol 1986;108:399-403.
7. Quadri SK, Lu KH, Meites J: Ergot-induced inhibition of pituitary tumor growth in rats. Science 1972;176:417-418.
8. MacLeod RM, Lehmeyer JE: Suppression of pituitary tumor growth and function by ergot alkaloids. Cancer Res 1973;33:849-855.
9. Prysor-Jones RA, Jenkins JS: Effect of bromocriptine on DNA synthesis, growth and hormone secretion of spontaneous pituitary tumours in the rat. J Endocrinol 1981;88:463-469.
10. Sobrinho LG, Nunes MCP, Santos MA, Mauricio JC: Radiological evidence for regression of prolactinoma after treatment with bromocriptine. Lancet 1978;ii:257-258.
11. McGregor AM, Scanlon MF, Hall K, Cook DB, Hall R: Reduction in size of a pituitary tumor by bromocriptine therapy. N Engl J Med 1979; 300:291-293.
12. Thorner MO, Martin WH, Rogol AD, Morris JL, Perryman RL, Conway BP, Howards SS, Wolfman MG, MacLeod RM: Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab 1980;51:438-445.
13. Takahashi S, Okazaki K, Kawashima S: Mitotic activity of prolactin cells in the pituitary glands of male and female rats of different ages. Cell Tissue Res 1984;235:497-502.
14. Hashi A, Mazawa S, Kato J, Arita J: Pentobarbital anesthesia during the proestrous afternoon blocks lactotroph proliferation occurring on estrus in female rats. Endocrinology 1995; 136:4665-4671.
15. Hashi A, Mazawa S, Chen SY, Yamakawa K, Kato J, Arita J: Estradiol-induced diurnal changes in lactotroph proliferation and their hypothalamic regulation in ovariectomized rats. Endocrinology 1996;137:3246-3252.
16. Sarkar DK, Gottschall PE, Xie QW, Meites J: Reduced tuberoinfundibular dopaminergic neuronal function in rats with in situ prolactin-secreting pituitary tumors. Neuroendocrinology 1984;38:498-503.
17. Demarest KT, Riegle GD, Moore KE: Long-term treatment with estradiol induces reversible alterations in tuberoinfundibular dopaminergic neurons: A decreased responsiveness to prolactin. Neuroendocrinology 1984;39: 193-200.
18. Arita J, Kimura F: Direct inhibitory effect of long term estradiol treatment on dopamine synthesis in tuberoinfundibular dopaminergic neurons: In vitro studies using hypothalamic slices. Endocrinology 1987;121:692-698.
19. Arita J, Kojima Y, Kimura F: Enhanced dopamine synthesis and release in vitro in the median eminence of rat hypothalamus are associated with involution of estradiol-induced pituitary tumors. Endocrinology 1989;124:1998-2004.
20. Pawlikowski M, Kunert-Radek J, Stepien H: Direct antiproliferative effect of dopamine agonists on the anterior pituitary gland in organ culture. J Endocrinol 1978;79:245-246.
21. Melmed S: Bromocriptine inhibits colony formation by rat pituitary tumor cells in a double-layered agar clonogenic assay. Endocrinology 1981;109:2258-2260.
22. Arafah BM, Wilhite BL, Rainieri J, Brodkey JS, Pearson OH: Inhibitory action of bromocriptine and tamoxifen on the growth of human pituitary tumors in soft agar. J Clin Endocrinol Metab 1983;57:986-992.
23. Prysor-Jones RA, Jenkins JS: Effect of bromocriptine, ergotamine and other ergot alkaloids on the hormone secretion and growth of a rat pituitary tumour. J Endocrinol 1980;86:147-153.
24. 3 tumor cells. Am J Obstet Gynecol 1985;153:349-357.
25. 3H]thymidine into rat pituitary tumor cells. Brain Res 1986;369: 83-90.
26. Florio T, Pan MG, Newman B, Hershberger RE, Civelli O, Stork PJS: Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity. J Biol Chem 1992;267:24169-24172.
27. 3 cells: A prolactin-secreting clone resistant to the inhibitory action of dopamine. Endocrinology 1980;106:718-723.
28. 3 cell line. Endocrinology 1990;127:13-20.
29. Malarkey WB, Groshong JC, Milo GE: Defective dopaminergic regulation of prolactin secretion in a rat pituitary tumour cell line. Nature 1977;266:640-641.
30. 3 cells to the dopaminergic inhibition of prolactin. Endocrinology 1980;107:1022-1026.
31. Denef C, Baes M, Schramme C: Stimulation of prolactin secretion after short term or pulsatile exposure to dopamine in superfused anterior pituitary cell aggregates. Endocrinology 1984; 114:1371-1378.
32. Schettini G, Cronin MJ, MacLeod RM : Adenosine 3′,5′-monophosphate (cAMP) and calcium-calmodulin interrelation in the control of prolactin secretion: Evidence for dopamine inhibition of cAMP accumulation and prolactin release after calcium mobilization. Endocrinology 1983;112:1801-1807.
33. Shin SH, Stirling R: Ascorbic acid potentiates the inhibitory effect of dopamine on prolactin release in primary cultured rat pituitary cells. J Endocrinol 1988;118:287-294.
34. Arita J, Kojima Y, Kimura F: Identification by the sequential cell immunoblot assay of a subpopulation of rat dopamine-unresponsive lactotrophs. Endocrinology 1991;128:1887-1894.
35. Ben-Jonathan N, Oliver C, Weiner HJ, Mical RS, Porter JC: Dopamine in hypophysial portal plasma of the rat during the estrous cycle and throughout pregnancy. Endocrinology 1977;100:452-458.
36. Denef C, Manet D, Dewals R: Dopaminergic stimulation of prolactin release. Nature 1980; 285:243-246.
37. 2 receptor subtype mediates dopaminergic stimulation of prolactin secretion from the anterior pituitary gland. Neuroendocrinology 1991;54:175-183.
38. Porter TE, Grandy D, Bunzow J, Wiles CD, Civelli O, Frawley LS: Evidence that stimulatory dopamine receptors may be involved in the regulation of prolactin secretion. Endocrinology 1994;134:1263-1268.
39. Denef C: Mechanism of action of pituitary hormone releasing and inhibiting factors; in Cooke BA, King RJB, van der Molen HJ (eds): Hormones and Their Actions. Part II. Amsterdam, Elsevier Science, 1988, pp 113-134.
40. Billestrup N, Swanson LW, Vale W: Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. Proc Natl Acad Sci USA 1986;83:6854-6857.
41. Antakly T, Pelletier G, Zeytinoglu F, Labrie F: Changes of cell morphology and prolactin secretion induced by 2-Br-α-ergocryptine, estradiol, and thyrotropin-releasing hormone in rat anterior pituitary cells in culture. J Cell Biol 1980;86:377-387.
42. Ingber DE, Folkman J: Tension and compression as basic determinants of cell form and function: Utilization of a cellular tensegrity mechanism; in Stein WD, Bronner F (eds): Cell Shape: Determinants, Regulation, and Regulatory Role. New York, Academic Press, 1989, pp 3-31.
43. Luna EJ, Hitt AL: Cytoskeleton-plasma membrane interactions. Science 1992;258:955-964.
44. Bussey H: Cell shape determination: A pivotal role for Rho. Science 1996;272:224-225.
45. Thorner MO, Perryman RL, Rogol AD, Conway BP, MacLeod RM, Login IS, Morris JL: Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 1981;53:480-483.
46. Tindall GT, Kovacs K, Horvath E, Thorner MO: Human prolactin-producing adenomas and bromocriptine: A histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 1982;55:1178-1183.
47. Rengachary SS, Tomita T, Jefferies BF, Watanabe I: Structural changes in human pituitary tumor after bromocriptine therapy. Neurosurgery 1982;10:242-251.
48. Hassoun J, Jaquet P, Devictor B, Andonian C, Grisoli F, Gunz G, Toga M: Bromocriptine effects on cultured human prolactin-producing pituitary adenomas: In vitro ultrastructural, morphometric, and immunoelectron microscopic studies. J Clin Endocrinol Metab 1985; 61:686-692.
49. Landolt AM, Osterwalder V, Landolt TA: Bromocriptine-induced removal of endoplasmic membranes from prolactinoma cells. Experientia 1985;41:640-642.
50. Folkman J, Moscona A: Role of cell shape in growth control. Nature 1978;273:345-349.
51. Hansen LK, Mooney DJ, Vacanti JP, Ingber DE: Integrin binding and cell spreading on extracellular matrix act at different points in the cell cycle to promote hepatocyte growth. Mol Biol Cell 1994;5:967-975.
52. Chen Q, Kinch MS, Lin TH, Burridge K, Juliano RL: Integrin-mediated cell adhesion activates mitogen-activated protein kinases. J Biol Chem 1994;269:26602-26605.
53. Zhu X, Assoian RK: Integrin-dependent activation of MAP kinase: A link to shape-dependent cell proliferation. Mol Biol Cell 1995;6: 273-282.
54. Campbell JS, Seger R, Graves JD, Graves LM, Jensen AM, Krebs EG: The MAP kinase cascade. Rec Prog Horm Res 1995;50:131-159.